Sanofi Consumer Healthcare India Limited has delivered exceptional Q3 financial performance, demonstrating robust growth across key metrics. The consumer healthcare company reported strong quarterly results with net profit surging 50% year-on-year, reflecting the company's effective execution strategies and market strength.

Q3 Financial Performance Highlights

The third quarter results showcase remarkable growth momentum across all major financial parameters, with the company maintaining strong profitability and revenue expansion.

Revenue and Profitability Analysis

The company's revenue performance demonstrates strong market traction with total revenue reaching ₹2.50 billion compared to ₹1.70 billion in the corresponding quarter of the previous year. This substantial revenue growth of over 47% reflects the company's successful market strategies and product portfolio strength.

Net profit performance has been particularly impressive, with earnings jumping to ₹665 million from ₹443 million year-on-year. This 50% increase in profitability showcases the company's ability to effectively convert revenue growth into bottom-line results.

EBITDA Performance and Margin Analysis

EBITDA for the quarter reached ₹898 million, representing a significant increase from ₹621 million in the same period last year, marking a growth of 44.61%. However, the EBITDA margin contracted slightly to 35.78% from 36.38% in the previous year, indicating a marginal impact on operational efficiency despite strong absolute growth.

Market Position and Growth Trajectory

The strong quarterly performance reinforces Sanofi Consumer Healthcare's position as a leading player in the Indian consumer healthcare segment. The company's ability to deliver consistent growth across revenue and profitability metrics demonstrates its resilient business model and effective market execution capabilities.

The robust financial results reflect the company's strategic focus on core portfolio strength and operational excellence, positioning it well for sustained growth in the competitive consumer healthcare market.

Sanofi Consumer Healthcare India Limited announced the designation of two senior executives as Senior Management Personnel following a board meeting held on February 25, 2026. The decision reflects the company's strategic focus on strengthening its leadership structure across key operational areas.

Board Decision and Regulatory Compliance

The Board of Directors, acting on recommendations from the Nomination & Remuneration Committee, designated Ms. Nupur Gurbaxani and Mr. Viral Shah as Senior Management Personnel effective February 25, 2026. The board meeting commenced at 2:00 p.m. and concluded at 5:20 p.m.

The company made this disclosure pursuant to Regulation 30 read with Para A(7) of Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notification was sent to both BSE Limited and National Stock Exchange of India Limited as per regulatory requirements.

Senior Management Personnel Details

Ms. Nupur Gurbaxani - Brand & Innovation Leadership

Ms. Gurbaxani serves as Director of Brand & Innovation and has been instrumental in driving the company's brand penetration turnaround since joining in July 2024. She brings a consumer-centric approach with sharp insights, innovative campaigns, and digital-first strategies.

An alumna of NMIMS, she possesses over 18 years of extensive experience across leading consumer and healthcare companies including Godrej Consumer Products, Novartis, and Abbott Nutrition. Her expertise positions her to play a critical role in the company's brand transformation and future growth initiatives.

Mr. Viral Shah - Manufacturing Excellence

Mr. Shah holds the position of Director of External Manufacturing and has been driving key infrastructure development initiatives since joining in May 2024. His focus areas include developing partnerships and capabilities to support the company's "Make In India" strategy across product lines.

A graduate of KJ Somaiya Institute of Management, he brings over 20 years of manufacturing and pharmaceutical industry experience from prominent organizations including Torrent, Ranbaxy Laboratories, Merck & Co., and Bayer. His strategic insight and industry expertise are expected to strengthen manufacturing capabilities and accelerate export growth from India.

Strategic Implications

The designation of these executives as Senior Management Personnel underscores Sanofi Consumer Healthcare India's commitment to strengthening its operational leadership. Both appointments align with the company's strategic priorities in brand innovation and manufacturing excellence, positioning the organization for enhanced market performance and growth acceleration. The formal notification to stock exchanges demonstrates the company's adherence to regulatory compliance and transparency standards.